explore -WSS

explore

author：entertainment 2025-09-27 13:03:20 - browse：216

A display of TVs against an orange background. -- health policy coverage from STAT — Adobe

WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in television drug commercials or require subtitles about side effects, a regulation that’s been 13 years in the making.

White House budget experts are reviewing changes to the regulation of broadcast drug advertisements that the Food and Drug Administration proposed in 2010, according to the Office of Management and Budget website. That proposal aimed to make commercials present drug risks in a manner that consumers notice and understand.

Drug ads have long been controversial. Aside from New Zealand, the United States is the only country that allows drug makers to advertise to consumers. Critics of drug ads say they pose consumer safety concerns by bombarding the public with promotions that distract viewers from potential side effects. Drug companies say commercials spark conversations between patients and doctors that promote clinically beneficial prescribing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Senate panel eyes new effort on drug shortages

WSS

What health policies could hitch a ride on a spending bill?

3 questions for the future of Biden's cancer moonshot

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Publishing genetic code of viruses could cause disaster

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

NIH chief: government has fallen behind pharma on clinical trials

hotspot

explore

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A Q&A with the global head of Boehringer Ingelheim's innovation unit

The cancer drug shortage isn’t new — and neither are the solutions

Why Charlie Gard's case is so disturbing to Americans

United colonoscopy coverage change 'may cost lives,' doctors say

3 questions for the future of Biden's cancer moonshot

Medical records are filled with copy

Analysis of telehealth claims data suggest service duplication

Walensky prepares to leave CDC — and Congress — behind

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

explore

Histogen: Failed biotech offers rare public look inside

What to expect at HLTH 2023, the health care industry conference

Liquid biopsy for lung cancer is launched by Delfi

Liquid biopsy for lung cancer is launched by Delfi

Histogen: Failed biotech offers rare public look inside

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

hotspot

focus

entertainment

entertainment